January might offer a new year reset, but chronic illness demands us to move forward and bring what we’ve learned, says ...

PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...

For guest writer Aranzazu Calzado, there's nothing like a wall to remind her that having something to lean on is not about ...

Artificial intelligence (AI), using a simple blood test combined with standard brain images has, for the first time, been able to identify two biologically distinct types of multiple sclerosis (MS), ...

Immediately after occupational therapy (OT), people with multiple sclerosis may show small improvements in daily functioning and mental health-related quality of life (HR-QoL), but OT may have little ...

Multiple sclerosis (MS) is a chronic neurological disease characterized by nerve damage and consequent impairments in vision, ...

Kesimpta is a medication used to treat relapsing forms of multiple sclerosis (MS) and clinically isolated syndrome (CIS). Kesimpta comes as a solution inside single-dose prefilled injection pens or ...

Prof Nicholas Schwab and his colleagues found a biomarker which allows to tell in advance if therapy with glatirameracetate will be efficient in an individual MS patent. Treatment with interferon or ...

Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system, including the brain, spinal cord, and optic nerves. The body mistakenly attacks and damages the protective ...

One of the many MSAA resources available is the Multiple Sclerosis Information (MSi) Video Library. This extensive library features a growing collection of content including webinars, educational ...